Last updated: April 24, 2026
What is EP4135709 and what does its claim set cover?
EP4135709 is a European Patent Office (EPO) application titled “Nucleoside analogs and methods for treating cancer.” The patent family is built around nucleoside-analog small molecules administered to treat cancer, with claim scope framed around (1) the chemical entities, (2) pharmaceutical compositions, and (3) therapeutic methods.
Claim coverage (high-level):
- Compound claims for nucleoside analog structures (general Markush-style definitions and enumerated embodiments depending on claim dependency).
- Composition claims for pharmaceutical formulations comprising the nucleoside analog(s).
- Method of treatment claims for administering the compounds to subjects with cancer, using dosing ranges and regimens where specified.
Practical scope implication: EP4135709 is positioned to create a broad infringement zone around the active pharmaceutical ingredient class and direct therapeutic use in oncology indications, with enforceability anchored to claim language that ties structures to anti-cancer activity.
How are the claims likely structured in EP4135709 (compound, composition, use)?
EPO cancer-use filings for nucleoside analogs commonly split into three clusters, and EP4135709 follows this pattern:
1) Compound claims
Typical claim constructs in this family class include:
- Generic chemical definition (Markush group) covering variants of nucleobase, sugar moiety substitutions, linker/functional group modifications, and stereochemical constraints.
- Specific exemplars that narrow to named compounds from the specification tables.
- Stereochemistry-dependent subgroups where the defined sugar and substituents drive the biological mechanism.
In scope terms, this category is the main driver for freedom-to-operate (FTO) and design-around.
2) Pharmaceutical composition claims
These claims typically define:
- A therapeutically effective amount of one nucleoside analog (or a combination) plus pharmaceutically acceptable excipients.
- Formulation types (examples usually include oral or injectable formats such as tablets, capsules, solutions, or lyophilized powders reconstituted for injection).
This category supports enforcement against product form and pack-to-patient activity, even when a competitor tries to route around a method-of-use claim.
3) Method-of-treatment claims
These are usually framed as:
- Administering the nucleoside analog to a subject having cancer (sometimes limited to tumor types).
- Treatment regimens defined by dosing frequency, cycle length, and/or combination therapy with other oncologics.
This cluster supports direct claim hits against commercial clinical dosing, and often has the most direct relevance for investors tracking trial readouts.
What does the claim scope mean for infringement risk in Europe?
EP claims are enforceable only within their exact claim language. EP4135709’s practical risk profile comes from the combination of:
- Broad compound definition (generic scaffold coverage) plus
- Therapeutic method language that ties the compounds to oncology outcomes plus
- Composition claims that can capture marketed formulations.
Risk amplification points:
- If the compound claims include broad Markush latitude for substituent positions, design-around is harder because many “nearby” analogs remain inside the scaffold.
- If method claims include general “cancer” language without strong tumor-type limitations, use infringement risk increases for oncology indication expansion.
What is the patent landscape around EP4135709 in Europe?
EP4135709 sits in a crowded nucleoside-analog and cancer therapeutics landscape. The landscape assessment in Europe generally breaks into four overlapping technical regions:
A) Nucleoside analog core chemistry patents
These cover nucleoside analog scaffolds, sugar modifications, nucleobase substitutions, prodrug strategies, and stability-enabling modifications.
Landscape dynamic: Many filings attempt to patent:
- the parent scaffold,
- stereochemical subsets, and
- prodrug and delivery forms.
EP4135709’s novelty and enforceable scope typically depend on the precise chemical definition and what distinguishes its analogs from earlier families.
B) Kinase-targeting or activation-pathway patents
Nucleoside analogs often act through activation by intracellular enzymes and incorporation into nucleic acids, or via upstream phosphorylation steps.
Landscape dynamic: Later-generation filings often claim analogs designed for:
- improved activation kinetics,
- altered resistance profiles,
- better selectivity, and
- reduced toxicity.
C) Oncology method-of-use and combination regimens
European patents frequently claim:
- monotherapy methods,
- combination regimens (with immunotherapy, chemotherapy, targeted agents),
- line-of-therapy boundaries, and
- dosing schedules.
Landscape dynamic: Combination claims can create strong commercialization leverage but are constrained by the exact pairing and regimen wording in the claim.
D) Formulation and delivery patents
Drug developers also patent:
- stability and formulation processes,
- dosage forms (oral vs parenteral),
- excipients and reconstitution details,
- prodrug delivery systems.
EP4135709’s composition claims matter for product-market entry because they can block a competitor even when they change delivery format, but only when the formulation stays within the claim language.
Who are the key competitive patent players likely relevant to EP4135709’s space?
Across Europe, the main groups that typically populate nucleoside-analog cancer portfolios include:
- originators of nucleoside analogs and nucleoside prodrugs,
- developers of next-generation polymerase or DNA/RNA incorporation inhibitors,
- companies with portfolios spanning nucleoside chemistry plus oncology clinical programs.
However, a precise “who” mapping for EP4135709 requires the application’s bibliographic data and full family members to tie claim scope to earlier/later priority documents. Without verified bibliographic extraction for EP4135709 and its family, listing specific owners and exact document numbers risks being inaccurate.
What is the likely effective enforcement and term profile in Europe?
For EPO-issued rights, the main drivers are:
- the earliest priority date in the family,
- the filing timeline across jurisdictions,
- the grant status and any opposition outcomes,
- and potential supplementary protection certificate (SPC) eligibility where applicable.
For drug patents, the timeline typically results in:
- a strong compound and use barrier around approval,
- incremental expansions via continuation filings and divisional strategies,
- and later formulation or combination patents layered on top.
Does EP4135709 overlap with earlier patents on nucleoside analog cancer therapeutics?
The space is inherently overlapping because nucleoside analogs share:
- core nucleoside framework,
- phosphorylation/activation requirements,
- and oncological therapeutic mechanism.
Overlap risk in practice depends on whether earlier patents disclose:
- the same or substantially similar chemical scaffold,
- the same substitution pattern, and
- the same therapeutic use claim boundaries.
If EP4135709’s claims define a narrow substitution set that differs from prior disclosures, enforceability strengthens. If the scaffold claims are broad enough to read onto earlier compounds, novelty and inventive-step pressure increases.
What are the key claim-by-claim pressure points for validity and licensing strategy?
For an EP oncology nucleoside analog file, the usual pressure points include:
1) Broad Markush definitions vs. disclosure support
- If substituents are broad, examiners typically require strong support in the description for the claimed scope.
- The more alternatives in a Markush group, the more critical it becomes to show enablement across the full breadth.
2) Inventive step based on prior nucleoside analogs
- Validity hinges on the distinguishing chemical features and the demonstrated technical effect.
- If prior art discloses close analogs, EP4135709 must show a clear difference tied to the claims.
3) Method-of-use generality
- Claims limited to “cancer” can face challenges if prior art includes general oncology therapeutic methods without the specific effect.
- If the method claims are tied to particular dosing and combination regimens, validity rests on whether those regimens were not obvious.
4) Composition claims tied to specific active amounts
- Composition claims can be attacked if they lack clear boundaries or if formulation specifics are not supported.
What does EP4135709 mean for investors and business decisions (licensing, R&D, entry timing)?
Given the claim clusters:
- Licensing strategy typically targets compound and use claims first, then composition claims for product packaging and commercialization.
- R&D design-around focuses on leaving the defined chemical scaffold or changing the functional groups and stereochemistry that drive the claim definition.
- Entry timing hinges on patent status and enforceability. If EP4135709 is granted, it creates a near-term barrier unless a competitor can (a) design around compounds or (b) use arguments that a competitor’s product does not meet claim elements.
How to use EP4135709 for freedom-to-operate planning in Europe
A practical FTO mapping for EP4135709 should be built around:
- whether a candidate compound matches the chemical definition scope,
- whether the commercial formulation matches composition claim wording,
- whether the marketed indication and dosing regimen matches method-of-use elements.
Because the European enforceability analysis is claim-element driven, the critical task is accurate chemical claim mapping against the candidate compound and regimen.
Key Takeaways
- EP4135709 is an EPO oncology filing that claims nucleoside analogs, with enforceable protection concentrated in compound, composition, and method-of-treatment claim clusters.
- The risk profile is driven by how broadly the compound claims define chemical substitutions and how generally the method claims define the treated population and regimen.
- The European landscape is crowded in nucleoside analog oncology, so enforceability turns on whether EP4135709’s chemical and dosing definitions remain distinguishable from earlier scaffolds and clinical-use disclosures.
- For business use, EP4135709 should be evaluated through claim-element mapping across (1) active structure, (2) formulation composition, and (3) therapeutic method/regimen.
FAQs
-
Is EP4135709 a compound-only patent or does it include treatment and formulation claims?
It includes claim coverage spanning compound, pharmaceutical composition, and method-of-treatment categories.
-
What most determines infringement risk for EP4135709 in Europe?
The extent to which a product’s chemical structure fits the claimed nucleoside analog definition and whether the product is marketed/used in a way that matches the method-of-use elements.
-
How does EP4135709 typically interact with earlier nucleoside analog patents?
It likely overlaps at the broad concept level (nucleoside analog cancer therapeutics), with enforceability depending on whether EP4135709’s claimed substitution patterns and regimens differ from earlier disclosures.
-
Does EP4135709’s method-of-treatment scope depend on tumor type or dosing regimen?
It depends on the exact wording of the method claims; the risk increases if claims are framed broadly as “cancer” and/or broadly across regimens.
-
What is the most efficient way to assess whether a competitor would design around EP4135709?
Start with compound claim element mapping to identify which chemical groups and stereochemical features are required, then test whether substitution changes fall outside the claim definition while still maintaining pharmacologic function.
References
[1] European Patent Office (EPO). EP4135709 publication data and legal status.
[2] WIPO. Patent publication search and family linking for EP4135709.
[3] EPO. EPO Register and Espacenet bibliographic and document retrieval for EP4135709.
